Drug company shares are down amid President Donald Trump’s assault on the industry, but some in Congress see value.

Merck & Co. Inc. closed 40.46% short of its 52-week high of $134.63, which the company reached on June 25th.

It is hard to think of a less coherent pair of policies: President Trump’s tax policy encourages the very offshoring that his ...

Johnson & Johnson is an impeccable dividend stock with a streak of 63 consecutive dividend raises. The company's long history ...

A few of the new members Health Secretary Robert F. Kennedy Jr. appointed to the federal panel have promoted misinformation ...

Despite a strong cash position and no debt, my NPV model shows NUVB is fairly valued or overvalued at $1.73. Click here to ...

Merck & Co., Inc. (NYSE:MRK) is another biopharmaceutical company on the list of the 10 undervalued blue chip stocks analysts ...

The company has raised its payouts for 14 consecutive years, and its nearly 89% growth over the last 10 years provides a ...

Big pharma competes bitterly with the tech giants for the title of most dodgy corporate sector in the world. Given this ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that scientific and commercial team leaders will host a virtual investor event where they will give an overview ...

Merck said that a phase-three study of its pulmonary arterial hypertension treatment met its primary endpoints.

Merck’s phase 3 HYPERION study of Winrevair meets primary endpoint in recently diagnosed adults with pulmonary arterial hypertension: Rahway, New Jersey Tuesday, June 24, 2025, ...